NMDA antagonist
AssigneeProtexeon Limited
InventorsNicholas Peter Franks, Mervyn Maze
Life of this patent
Estimating the term…
Loading patent…
AssigneeProtexeon Limited
InventorsNicholas Peter Franks, Mervyn Maze
Estimating the term…
The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the preparation thereof. Another aspect of the invention relates to a pharmaceutical composition suitable for providing neuroprotection, inhibiting synaptic plasticity or relieving neuropathic pain, said composition comprising xenon and a GABAergic agent admixed with a pharmaceutically acceptable carrier, excipient or diluent.
A pharmaceutical composition suitable for providing neuroprotection, inhibiting synaptic plasticity or relieving neuropathic pain, said composition comprising xenon and a GABAergic agent admixed with a pharmaceutically acceptable carrier, excipient or diluent.
A process for the preparation of a pharmaceutical composition suitable for providing neuroprotection, inhibiting synaptic plasticity or relieving neuropathic pain, which process comprises adding xenon and a GABAergic agent to a pharmaceutically acceptable carrier, excipient or diluent.
Use of xenon as a neuroprotectant, for inhibiting synaptic plasticity, or for relieving neuropathic pain.
A method for modulating the activity of an NMDA receptor in a mammal comprising administering to the mammal xenon in amounts effective to modulate the activity of said receptor.
A pharmaceutical composition suitable for providing neuroprotection, inhibiting synaptic plasticity or relieving neuropathic pain, said composition comprising xenon and a GABAergic agent admixed with a pharmaceutically acceptable carrier, excipient or diluent, wherein said xenon and said GABAergic agent are present in an amount sufficient to provide neuroprotection, inhibit synaptic plasticity or relieve neuropathic pain.
A method for modulating the activity of an NMDA receptor in a mammal comprising administering to the mammal in need of the same xenon in amounts effective to modulate the activity of said receptor.
Dependencies are inferred from the claim text.